Now, with the Forest deal, Actavis is expected to have combined annual sales of more than $15 billion in 2015.The Dublin, Ireland-based drugmaker's portfolio includes some 1,000 generic, branded generic, branded proprietary and over-the-counter pharmaceuticals for hypertension, pain, sleep disorders and other ailments.